All In Biotech

Drug Trial Radar · NCT07245953

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

A Clinical Study to Evaluate the Efficacy and Safety of HT-101 Injection Combined With HT-102 Injection in Patients With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Feb 2027

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.

Conditions

  • Chronic Hepatitis B

Interventions

  • HT-101Drug

    HT-101 given by subcutaneous injection

  • HT-102Drug

    HT-102 given by subcutaneous injection

  • HT-101 placeboDrug

    HT-101 placebo given by subcutaneous injection

  • HT-102 placeboDrug

    HT-102 placebo given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving HBsAg < lower limit of detection (LOD) 0.05 International Unit/mL (IU/mL) and HBV DNA < lower limit of quantitation (LLOQ) with or without anti-HBs seroconversion at W60Time frame: From enrollment to the end of treatment at up to 60 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Guangzhou Eighth People's Hospital, Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • Qingyuan People's Hospital

    Qingyuan, Guangdong, China

  • Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine

    Nanning, Guangxi, China

  • Henan Infectious Diseases Hospital , The Sixth People's Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • The Second Hospital of Nanjing

    Nanjing, Jiangsu, China

  • Zhenjiang Third People's Hospital (Zhenjiang Infectious Diseases Hospital)

    Zhenjiang, Jiangsu, China

  • Nanchang Ninth Hospital

    Nanchang, Jiangxi, China

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.